Department of Pediatrics, Cathay General Hospital, Taipei, Taiwan.
J Formos Med Assoc. 2013 Apr;112(4):230-2. doi: 10.1016/j.jfma.2012.10.011. Epub 2012 Dec 31.
Despite proven good efficacy of pneumococcal conjugated vaccine in preventing invasive pneumococcal disease, breakthrough infections remain a noticeable problem with significant morbidity and mortality, especially in selected high-risk groups. We present a 2-year-old girl with infantile spasm, who was treated with antiepileptic drugs and adrenocorticotropic hormone (ACTH). Vaccination with three doses 7-valent pneumococcal conjugate vaccine had been completed one month before ACTH therapy. Two months after ACTH therapy, she suffered from fever, cough, and decreased activity. Streptococcus pneumoniae, serotype 6B, was detected in blood culture. Vaccine failure could be possibly due to ACTH therapy.
尽管已证实肺炎球菌结合疫苗在预防侵袭性肺炎球菌病方面具有良好的疗效,但突破性感染仍是一个值得关注的问题,尤其是在某些高危人群中,其发病率和死亡率都较高。我们介绍了一位 2 岁的女孩,她患有婴儿痉挛症,正在接受抗癫痫药物和促肾上腺皮质激素(ACTH)治疗。在 ACTH 治疗前一个月,她已完成了 3 剂 7 价肺炎球菌结合疫苗的接种。在 ACTH 治疗后 2 个月,她出现发热、咳嗽和活动减少。血培养检出 6B 型肺炎链球菌。ACTH 治疗可能导致疫苗失效。